Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Cash & Equivalents for 6 consecutive years, with $11.8 million as the latest value for Q3 2021.

  • Quarterly Cash & Equivalents rose 210.9% to $11.8 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $11.8 million through Sep 2021, up 210.9% year-over-year, with the annual reading at $7.2 million for FY2020, 17.06% up from the prior year.
  • Cash & Equivalents for Q3 2021 was $11.8 million at ENDRA Life Sciences, down from $14.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $16.8 million in Q1 2021, with the low at $133679.0 in Q1 2017.
  • Average Cash & Equivalents over 5 years is $5.5 million, with a median of $3.9 million recorded in 2019.
  • The sharpest move saw Cash & Equivalents soared 9136.41% in 2017, then plummeted 90.87% in 2018.
  • Over 5 years, Cash & Equivalents stood at $5.6 million in 2017, then rose by 15.52% to $6.5 million in 2018, then decreased by 4.59% to $6.2 million in 2019, then increased by 17.06% to $7.2 million in 2020, then skyrocketed by 63.18% to $11.8 million in 2021.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $11.8 million, $14.0 million, and $16.8 million for Q3 2021, Q2 2021, and Q1 2021 respectively.